Activity in this selectionOct 18, 2026 · Jul 21, 2026
SBI US Gateway Fund is the specified investment vehicle named by Sift and Typewriter.
Recorded funding activity
Sift develops peptide immunotherapies using AI and profiling. Typewriter develops RNA-based insertion of therapeutic genes. These financing relationships belong to the named vehicle rather than to every SBI group entity.
Typewriter Therapeutics is developing an all-RNA gene-writing platform that inserts therapeutic genes at a defined genomic site without viral vectors or double-strand DNA breaks. Its programs target in vivo engineered CAR-T cells and gene insertion for severe genetic diseases, including liver disorders.